NancyLeeBartlettMD

Oncology • Saint Louis, MO

Hematologic Oncology

Professor, Internal Medicine, Washington University School of Medicine

Join to view full profile

Dr. Bartlett is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Bartlett's full profile

Already have an account?

Office
4921 Parkview Pl
7th Floor
Saint Louis, MO 63110
Phone+1 314-747-1171

Fax+1 314-361-3192
Is this information wrong?

Education & Training

Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 1990 - 1993
University of California (San Francisco)Internship, Internal Medicine, 1986 - 1987
Washington University in St. Louis School of MedicineClass of 1986

Certifications & Licensure

CA State Medical License 1988 - Present
MO State Medical License 1993 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012

Clinical Trials

Aminocamptothecin in Treating Patients With Refractory or Recurrent Hodgkin's Disease or Non-Hodgkin's Lymphoma Start of enrollment: 1996 Apr 01
Completed
Phase 2
Etoposide in Treating Patients With Relapsed Non-Hodgkin's Lymphoma Start of enrollment: 1996 Nov 01
Completed
Phase 2
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma Start of enrollment: 1999 Jun 17
Completed
Phase 3
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma Start of enrollment: 2000 Jul 01
Completed
Phase 1, Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma Start of enrollment: 2000 Jul 01
Completed
Phase 2
Cytogenetic Studies in Acute Leukemia and Multiple Myeloma Start of enrollment: 1984 Jun 01
Active, not recruiting
FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Start of enrollment: 2004 Jan 01
Completed
Phase 2
Xcellerated T CellsTM for Non-Hodgkin's Lymphoma (NHL) Patients Start of enrollment: 2004 Mar 01
Unknown status
Phase 2
Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma Start of enrollment: 2005 May 01
Completed
Phase 3
Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab Start of enrollment: 2006 Mar 01
Completed
Phase 2
Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies Start of enrollment: 2006 Nov 01
Completed
Phase 1
Forodesine in the Treatment of Cutaneous T-Cell Lymphoma Start of enrollment: 2007 Jul 01
Completed
Phase 2
Bortezomib and Lenalidomide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma Start of enrollment: 2007 Nov 15
Completed
Phase 2
Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia Start of enrollment: 2008 Jan 15
Completed
Phase 2
S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma Start of enrollment: 2009 Jul 01
Completed
Phase 2
Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma Start of enrollment: 2009 May 05
Active, not recruiting
Phase 2
Collecting and Storing Blood, Bone Marrow, and Other Samples From Patients With Acute Leukemia, Chronic Leukemia, or Myelodysplastic Syndromes Start of enrollment: 1996 May 01
Active, not recruiting
Study of Biomarkers in Blood and Bone Marrow Samples From Patients With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2009 Oct 01
Completed
Response-Based Therapy Assessed By PET Scan in Treating Patients With Bulky Stage I and Stage II Classical Hodgkin Lymphoma Start of enrollment: 2010 Sep 01
Completed
Phase 2
Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma Start of enrollment: 2010 May 01
Completed
Phase 2
Ofatumumab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma Start of enrollment: 2011 Aug 01
Completed
Phase 2
Lenalidomide Maintenance Therapy Post Autologous Transplant for Hodgkins Lymphoma Start of enrollment: 2011 Apr 28
Completed
Phase 1
Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma Start of enrollment: 2011 Apr 08
Active, not recruiting
Phase 2
S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma Start of enrollment: 2011 Sep 01
Completed
Phase 2
S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma Start of enrollment: 2011 Nov 01
Completed
Phase 2
A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma Start of enrollment: 2011 Aug 01
Completed
Phase 2
A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma Start of enrollment: 2011 Oct 13
Completed
Phase 2
Phase I/II Study of Abraxane in Recurrent and Refractory Lymphoma Start of enrollment: 2012 Jul 01
Terminated
Phase 1
ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas Start of enrollment: 2013 Jan 31
Completed
Phase 3
Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma Start of enrollment: 2013 Dec 05
Completed
Phase 1
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2013 Dec 09
Active, not recruiting
Phase 3
Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL) Start of enrollment: 2013 Aug 01
Terminated
Phase 2
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Start of enrollment: 2014 Feb 20
Active, not recruiting
Phase 3
Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma Start of enrollment: 2014 Sep 18
Completed
Phase 1
Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas Start of enrollment: 2015 Feb 04
Completed
Phase 1
Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma Start of enrollment: 2016 May 13
Active, not recruiting
Phase 2
Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas Start of enrollment: 2017 Feb 06
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study.
Lihua E Budde, Sarit Assouline, Laurie H Sehn, Stephen J Schuster, Sung-Soo Yoon, Dok Hyun Yoon, Matthew J Matasar, Francesc Bosch, Won Seog Kim, Loretta J Nastoupil, ...> ;Journal of Clinical Oncology. 2024 Mar 28
Impact of imaging frequency on progression-free survival in Alliance trials enrolling patients with follicular lymphoma.
Sarah C Rutherford, Jun Yin, Levi D Pederson, Kristie A Blum, Peter Martin, Sin-Ho Jung, Barbara Grant, Cara Rosenbaum, Bruce D Cheson, Nancy L Bartlett, Sumithra J Ma...> ;Blood Advances. 2024 Mar 26
1 citations
Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas.
Stephen J Schuster, Ling-Yuh Huw, Christopher R Bolen, Victor Maximov, Andrew G Polson, Katerina Hatzi, Elisabeth A Lasater, Sarit E Assouline, Nancy L Bartlett, L Eli...> ;Blood. 2024 Feb 29
Long-term Follow-up from A041202 Shows Continued Efficacy of Ibrutinib Regimens for Older Adults with CLL.
Barr, P. M., Barr, P. M., Barr, P. M., Jennifer A Woyach, Gabriela E Perez Burbano, Amy S Ruppert, Cecelia R Miller, Nyla A Heerema, Weiqiang Zhao, Anna Wall, Wei Ding...> ;Blood. 2024 Jan 12
Outcomes of marginal zone lymphoma treated with ibrutinib in the first-line setting in the United States: a real-world analysis.
Epperla, N., Narendranath Epperla, Qiuhong Zhao, Tamara Moyo, Marcus P Watkins, Montreh Tavakkoli, Celeste Bello, Pallawi Torka, Nishitha Reddy, Colin Thomas, Kaitlin ...> ;Blood Advances. 2024 Feb 13
Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II Trial.
Matthew Matasar, Nancy L Bartlett, Mazyar Shadman, Lihua E Budde, Ian Flinn, Gareth P Gregory, Won Seog Kim, Georg Hess, Dima El-Sharkawi, Catherine S Diefenbach, Huan...> ;Clinical Lymphoma, Myeloma & Leukemia. 2024 Apr 1
Brentuximab vedotin with chemotherapy in adolescents and young adults with stage III or IV classical Hodgkin lymphoma in ECHELON-1.
Howland E Crosswell, Ann S LaCasce, Nancy L Bartlett, David J Straus, Kerry J Savage, Pier Luigi Zinzani, Graham P Collins, Michelle Fanale, Keenan Fenton, Cassie Dong...> ;Haematologica. 2024 Mar 1
Impact of circulating lymphoma cells at diagnosis on outcomes in patients with marginal zone lymphoma: a multicenter cohort study.
Kaitlin Annunzio, Natalie S Grover, Rina Li Welkie, Pallawi Torka, Marcus P Watkins, Andrea Anampa-Guzmán, Montreh Tavakkoli, Timothy S Oh, Heather Reves, Daniel Jones...> ;Blood Advances. 2023 Nov 28
Prognostic factors for adult patients with Burkitt lymphoma treated with dose-adjusted EPOCH-R.
Rahul Lakhotia, Kieron Dunleavy, Jeremy S Abramson, Brian K Link, Bayard L Powell, Christopher Melani, Andrea N Lucas, Seth M Steinberg, Jonathan W Friedberg, Brad S K...> ;Blood Advances. 2023 Sep 26
3 citations
Impact of detectable monoclonal protein at diagnosis on outcomes in marginal zone lymphoma: a multicenter cohort study.
Narendranath Epperla, Qiuhong Zhao, Reem Karmali, Pallawi Torka, Lauren Shea, Timothy S Oh, Andrea Anampa-Guzmán, Heather Reves, Montreh Tavakkoli, Irl Brian Greenwell...> ;Blood Advances. 2023 Sep 12
5 citations
Impact of early relapse within 24 months after first-line systemic therapy (POD24) on outcomes in patients with marginal zone lymphoma: A US multisite study.
Narendranath Epperla, Rina Li Welkie, Pallawi Torka, Geoffrey Shouse, Reem Karmali, Lauren Shea, Andrea Anampa-Guzmán, Timothy S Oh, Heather Reaves, Montreh Tavakkoli,...> ;Journal of Hematology & Oncology. 2023 May 8
10 citations
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma.
Nancy L Bartlett, Sarit Assouline, Pratyush Giri, Stephen J Schuster, Chan Y Cheah, Matthew Matasar, Gareth P Gregory, Dok Hyun Yoon, Mazyar Shadman, Keith Fay, Sung-S...> ;Blood Advances. 2023 Sep 12
47 citations
Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma.
Sattva S Neelapu, Caron A Jacobson, Armin Ghobadi, David B Miklos, Lazaros J Lekakis, Olalekan O Oluwole, Yi Lin, Ira Braunschweig, Brian T Hill, John M Timmerman, Abh...> ;Blood. 2023 May 11
1 citations
Is local review of positron emission tomography scans sufficient in diffuse large B-cell lymphoma clinical trials? A CALGB 50303 analysis.
Pallawi Torka, Levi D Pederson, Michael V Knopp, David Poon, Jun Zhang, Brad S Kahl, Howard R Higley, Gary Kelloff, Jonathan W Friedberg, Lawrence H Schwartz, Wyndham ...> ;Cancer Medicine. 2023 Apr 1
4 citations
Navigating the Evolving Treatment Landscape of Diffuse Large B-Cell Lymphoma.
Loretta J Nastoupil, Nancy L Bartlett> ;Journal of Clinical Oncology. 2023 Feb 1
2 citations
Postibrutinib relapse outcomes for patients with marginal zone lymphoma.
Narendranath Epperla, Qiuhong Zhao, Sayan Mullick Chowdhury, Lauren Shea, Tamara K Moyo, Nishitha Reddy, Julia Sheets, David M Weiner, Praveen Ramakrishnan Geethakumar...> ;Blood Advances. 2023 Jan 10
4 citations
Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials.
Rutherford, S., Yin, J., Pederson, L., Perez Burbano, G., LaPlant, B., Shadman, M., Li, H., LeBlanc, M., Kenkre, V., Hong, F., Blum, K., Dockter, T., Martin, P., Jung,...> ;Journal of Clinical Oncology. 2023 Jan 10
3 citations
Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 study.
John Kuruvilla, Philippe Armand, Mehdi Hamadani, Justin Kline, Craig H Moskowitz, David Avigan, Joshua D Brody, Vincent Ribrag, Alex F Herrera, Franck Morschhauser, Ab...> ;Leukemia & Lymphoma. 2023 Jan 1
8 citations
Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma.
Deepa Jagadeesh, Steve Horwitz, Nancy L Bartlett, Youn Kim, Eric Jacobsen, Madeleine Duvic, Meredith Little, William Trepicchio, Keenan Fenton, Matthew Onsum, Julie Li...> ;The Oncologist. 2022 Oct 1
75 citations
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study.
Lihua E Budde, Laurie H Sehn, Matthew Matasar, Stephen J Schuster, Sarit Assouline, Pratyush Giri, John Kuruvilla, Miguel Canales, Sascha Dietrich, Keith Fay, Matthew ...> ;The Lancet. Oncology. 2022 Aug 1
4 citations
Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study.
Narendranath Epperla, Qiuhong Zhao, Sayan Mullick Chowdhury, Lauren Shea, Tamara K Moyo, Nishitha Reddy, Julia Sheets, David M Weiner, Praveen Ramakrishnan Geethakumar...> ;Journal of Hematology & Oncology. 2022 Jul 16
1 citations
COVID-19 booster vaccines generate seroconversion in subset of patients with lymphoma/CLL: single institution experience.
Neha Mehta-Shah, Nancy L Bartlett, Brad Kahl, Marcus P Watkins, Amalia Dubois, Gabby Schmelzle, Saiama Waqar, Claire Ballman, Fei Wan, Christopher W Farnsworth> ;Leukemia & Lymphoma. 2022 Jul 1
6 citations
Outcomes Among Classical Hodgkin Lymphoma Patients After an Interim PET Scan: A Real-World Experience.
Muhammad Saad Hamid, Sarah C Rutherford, Hyejeong Jang, Seongho Kim, Krish Patel, Nancy L Bartlett, Mary-Kate Malecek, Marcus P Watkins, Kami J Maddocks, David A Bond,...> ;Clinical Lymphoma, Myeloma & Leukemia. 2022 Jul 1
5 citations
Metabolic Biomarkers Assessed with PET/CT Predict Sex-Specific Longitudinal Outcomes in Patients with Diffuse Large B-Cell Lymphoma.
Shama Jaswal, Vanessa Sanders, Priyanka Pullarkat, Stephanie Teja, Amber Salter, Marcus P Watkins, Norman Atagu, Daniel R Ludwig, Joyce Mhlanga, Vincent M Mellnick, Li...> ;Cancers. 2022 Jun 14
3 citations
Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method survey.
R Andrew Harkins, Sharvil P Patel, Michelle J Lee, Jeffrey M Switchenko, Stephen M Ansell, Nancy L Bartlett, Kristie A Blum, Amanda F Cashen, Carla Casulo, Jonathan W ...> ;Blood Advances. 2022 May 10
Join now to see all

Journal Articles

CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma
Mark P Chao, Sonali M Smith, Ranjana Advani, Ian Flinn, Ravindra Majeti, Nancy L Bartlett, Leslie Popplewell, Justin Kline, Nilanjan Ghosh, Ann LaCasce, The New England Journal of Medicine
Rituximab with ABVD vs ABVD for Advanced Stage High-Risk Classical Hodgkin Lymphoma: A Randomized Phase II Study
Francesco Turturro, Luis E Fayad, Anas Younes, Michelle Fanale, Yasuhiro Oki, Hun Ju Lee, Nancy L Bartlett, Haematologica
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma
Ian W Flinn, Nancy L Bartlett, The New England Journal of Medicine
CALBG 50604: Risk-Adapted Treatment of Non-Bulky Early Stage Hodgkin Lymphoma Based on Interim PET
David J Straus, Heiko Schoder, Bruce D Cheson, John C Grecula, Lale Kostakoglu, Eric D Hsi, Leslie L Popplewell, John P Leonard, Craig H Moskowitz, Brad S Kahl, Jonath..., Blood
Sustained Efficacy and Detailed Clinical Follow-up of First-Line Ibrutinib Treatment in Older Patients with Chronic Lymphocytic Leukemia: Extended Phase 3 Results from...
Steven Coutre, Thomas J Kipps, Jan A Burger, Nancy L Bartlett, Paul M Barr, Haematologica
Join now to see all

Abstracts/Posters

North American Practice Patterns for PET-2 Positive Hodgkin Lymphoma
Nancy L. Bartlett, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
T-Cell Clonal Expansion and Activation Associated with Durable Clinical Response to Dual BTK and CDK4/6 Inhibitor Therapy in Mantle Cell Lymphoma
Nancy L Bartlett, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Composite Copy Number Variation in CDK4, CDKN2A and RB1 Predisposes Mantle Cell Lymphoma to Expansion of PD1+ Tumor Cells and Resistance to CDK4/6 Inhibitor Therapy as...
Nancy L. Bartlett, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A Comparison of Two-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel) and SCHOLAR-1 in Patients with Refractory Large B Cell Lymphoma
Nancy L Bartlett, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relap...
Nancy L Bartlett, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Pharmacodynamic Effects and Immune Correlates of Response to the CD20/CD3 Bispecific Antibody Mosunetuzumab in Relapsed or Refractory Non-Hodgkin Lymphoma
Nancy L Bartlett, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Validation of the PRIMA-Prognostic Index for Patients Treated with Rituximab Plus Chemotherapy and Refinement of Prognostic Parameters for Patients on Rituximab Plus L...
Nancy L. Bartlett, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
PET-Directed Therapy for Patients with Limited-Stage Diffuse Large B-Cell Lymphoma - Results of Intergroup Nctn Study S1001
Nancy L. Bartlett, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 Study
Nancy L. Bartlett, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Fitness and Anthracycline Use in Front-Line Therapy for Older Patients with Classical Hodgkin Lymphoma: A US Multi-Center Retrospective Analysis
Nancy L. Bartlett, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Romidepsin in Combination with Gemcitabine, Oxaliplatin, and Dexamethasone Shows Durable Responses in Aggressive Lymphomas
Nancy L. Bartlett, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

Managing cytokine release syndrome (CRS) and neurotoxicity with step-fractionated dosing of mosunetuzumab in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL).
ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019
Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 Study
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
A Phase 1b Study Investigating the Combination of the Tetravalent Bispecific NK Cell Engager AFM13 and Pembrolizumab in Patients with Relapsed/Refractory Hodgkin Lymph...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Rituximab/Bendamustine and Rituximab/Cytarabine (RB/RC) Induction Chemotherapy for Transplant-Eligible Patients with Mantle Cell Lymphoma: A Pooled Analysis of Two Pha...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Classic Hodgkin Lymphoma: Part 3 (Concurrent Dosing) Resul...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Bortezomib Maintenance (BM) or Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Brentuximab Vedotin with Chemotherapy in Adolescents and Young Adults (AYA) with Stage III or IV Hodgkin Lymphoma: A Subgroup Analysis from the Phase 3 Echelon-1 Study
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Lymphoma & Myeloma 2012: An International Congress on Hematologic Malignancies
Imedex, Naples, Florida - 10/25/2012
2012 American Society of Hematology State-of-the-Art Symposium
American Society of Hematology (ASH), Hollywood, California - 10/12/2012
Join now to see all

Press Mentions

At ASH, Regeneron Plays Catch-up with Its Next Cancer DrugsDecember 12th, 2022
$Bispecific Antibody Mosunetuzumab in Relapsed or Refractory Follicular Lymphoma$
Bispecific Antibody Mosunetuzumab in Relapsed or Refractory Follicular LymphomaJuly 12th, 2022
Pulling Back the Curtain: Bill Blum, MD, and Kristie Blum, MDMarch 1st, 2021
Join now to see all

Grant Support

Wumc Cancer And Leukemia Group BNational Cancer Institute2009–2012
Data And Safety MonitoringNational Cancer Institute2010–2011
Wumc-Cancer And Leukemia Group BNational Cancer Institute2003–2008
Quality Assurance And Safety MonitoringNational Cancer Institute2004
24hr Infusion Of Hmr1275 In Fludarabine--B Cell LeukemiaNational Center For Research Resources2000–2002
Wusm Cancer And Leukemia Group BNational Cancer Institute1998–2002
Coadmin Rising Oral Gg918 Dose Levels (GH120918) W/ Doxorubicin In Cancer PTSNational Center For Research Resources1998–1999